El Mourad Mona Blough, Amer Asmaa Fawzy
Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Tanta University, Tanta, Egypt.
Indian J Anaesth. 2018 Apr;62(4):285-291. doi: 10.4103/ija.IJA_791_17.
Pain after modified radical mastectomy (MRM) has been successfully managed with thoracic paravertebral block (TPVB). The purpose of this study was to evaluate the effect of adding dexamethasone or ketamine as adjuncts to bupivacaine in TPVB on the quality of postoperative analgesia in participants undergoing MRM.
This prospective randomised controlled study enrolled ninety adult females scheduled for MRM. Patients were randomised into three groups (30 each) to receive ultrasound-guided TPVB before induction of general anaesthesia. Group B received bupivacaine 0.5% + 1 ml normal saline, Group D received bupivacaine 0.5% + 1 ml dexamethasone (4 mg) and Group K received bupivacaine 0.5% + 1 ml ketamine (50 mg). Patients were observed for 24 h postoperatively to record time to first analgesic demand as a primary outcome, pain scores, total rescue morphine consumption and incidence of complications.
Group K had significantly longer time to first analgesic demand than group D and control group (18.0 ± 6.0, 10.3 ± 4.5 and 5.3 ± 3.1 hours respectively; = 0.0001). VAS scores were significantly lower in group D and group K compared to control group at 6h and 12 h postoperative (p 0.0001 and 0.0001 respectively) while group K had lower VAS at 18 hours compared to other two groups ( = 0.0001). Control group showed the highest mean 24 h opioid consumption (8.9 ± 7.9 mg) compared to group D and group K (3.60 ± 6.92 and 2.63 ± 5.24 mg, = 0.008,0.001 respectively). No serious adverse events were observed.
Ketamine 50 mg or dexamethasone 4 mg added to bupivacaine 0.5% in TPVB for MRM prolonged the time to first analgesic request with no serious side effects.
改良根治性乳房切除术(MRM)后的疼痛已通过胸椎旁神经阻滞(TPVB)成功控制。本研究的目的是评估在TPVB中,将地塞米松或氯胺酮作为布比卡因的辅助药物添加后,对接受MRM的参与者术后镇痛质量的影响。
这项前瞻性随机对照研究纳入了90名计划接受MRM的成年女性。患者被随机分为三组(每组30人),在全身麻醉诱导前接受超声引导下的TPVB。B组接受0.5%布比卡因+1毫升生理盐水,D组接受0.5%布比卡因+1毫升地塞米松(4毫克),K组接受0.5%布比卡因+1毫升氯胺酮(50毫克)。术后观察患者24小时,记录首次镇痛需求时间作为主要结局、疼痛评分、总挽救吗啡消耗量和并发症发生率。
K组首次镇痛需求时间明显长于D组和对照组(分别为18.0±6.0、10.3±4.5和5.3±3.1小时;P = 0.0001)。术后6小时和12小时,D组和K组的视觉模拟评分(VAS)明显低于对照组(分别为P = 0.0001和0.0001),而K组在18小时时的VAS低于其他两组(P = 0.0001)。与D组和K组相比,对照组的24小时平均阿片类药物消耗量最高(8.9±7.9毫克)(D组和K组分别为3.60±6.92和2.63±5.24毫克,P分别为0.008、0.001)。未观察到严重不良事件。
在MRM的TPVB中,向0.5%布比卡因中添加50毫克氯胺酮或4毫克地塞米松可延长首次镇痛请求时间,且无严重副作用。